Lian-sheng Qiao, Yu-su He, Xiao-qian Huo, Lu-di Jiang, Yan-kun Chen, Xi Chen, Yan-ling Zhang, Gong-yu Li. Construction and Evaluation of Merged Pharmacophore Based on Peroxisome Proliferator Receptor-Alpha Agonists[J]. Chinese Journal of Chemical Physics , 2016, 29(4): 508-516. doi: 10.1063/1674-0068/29/cjcp1602025
Citation: Lian-sheng Qiao, Yu-su He, Xiao-qian Huo, Lu-di Jiang, Yan-kun Chen, Xi Chen, Yan-ling Zhang, Gong-yu Li. Construction and Evaluation of Merged Pharmacophore Based on Peroxisome Proliferator Receptor-Alpha Agonists[J]. Chinese Journal of Chemical Physics , 2016, 29(4): 508-516. doi: 10.1063/1674-0068/29/cjcp1602025

Construction and Evaluation of Merged Pharmacophore Based on Peroxisome Proliferator Receptor-Alpha Agonists

doi: 10.1063/1674-0068/29/cjcp1602025
  • Received Date: 2016-02-22
  • Rev Recd Date: 2016-05-18
  • Pharmacophore is a commonly used method for molecular simulation, including ligand-based pharmacophore (LBP) and structure-based pharmacophore (SBP). LBP can be utilized to identify active compounds usual with lower accuracy, and SBP is able to use for distinguishing active compounds from inactive compounds with frequently higher missing rates. Merged pharmacophore (MP) is presented to integrate advantages and avoid shortcomings of LBP and SBP. In this work, LBP and SBP models were constructed for the study of peroxisome proliferator receptor-alpha (PPARα) agonists. According to the comparison of the two types of pharmacophore models, mainly and secondarily pharmacological features were identified. The weight and tolerance values of these pharmacological features were adjusted to construct MP models by single-factor explorations and orthogonal experimental design based on SBP model. Then, the reliability and screening efficiency of the best MP model were validated by three databases. The best MP model was utilized to compute PPARα activity of compounds from traditional Chinese medicine. The screening efficiency of MP model outperformed individual LBP or SBP model for PPARα agonists, and was similar to combinatorial screening of LBP and SBP. However, MP model might have an advantage over the combination of LBP and SBP in evaluating the activity of compounds and avoiding the inconsistent prediction of LBP and SBP, which would be beneficial to guide drug design and optimization.
  • 加载中
  • [1] S. Kar and K. Roy, Expert. Opin. Drug. Dis. 8, 245 (2013).
    [2] S. Gisbert, Nat. Rev. Drug. Dis. 9, 273 (2010).
    [3] G. H. Zeng, W. J. Wu, R. Zhang, J. Sun, W. G. Xie, and Y. Shen, Chin. J. Chem. Phys. 25, 297 (2012).
    [4] T. Kaserer, M. Höferl, K. Müller, S. Elmer, M. Ganzera, W. Jäger, and D. Schuster, Mol. Inform. 34, 431 (2015).
    [5] C. Zhi, L. H. Lin, Z. Q. Jun, B. X. Guang, Y. K. Qian, L. X. Min, Z. W. Liang, and J. H. Liang, Acta. Pharmacol. Sin. 30, 1694 (2009).
    [6] S. Thangapandian, S. John, S. Sakkiah, and K. W. Lee, Eur. J. Med. Chem. 46, 2469 (2011).
    [7] Y. Yang, F. Zou, L. Zhao, Y. Cheng, X. Zha, H. Zhang, and J. Zhou, Med. Chem. Res. 25, 585 (2016).
    [8] Y. Muftuoglu and G. Mustata, Bioorg. Med. Chem. Lett. 20, 3050 (2010).
    [9] P. Markt, D. Schuster, J. Kirchmair, C. Laggner, and T. Langer, J. Comput. Aided. Mol. Des. 21, 575 (2007).
    [10] B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J. C. Fruchart, Circulation 98, 2088 (1998).
    [11] J. Berger and D. E. Moller, Annu. Rev. Med. 53, 409 (2002).
    [12] P. Raval, M. Jain, A. Goswami, S. Basu, A. Gite, A. Godha, H. Pingali, S. Raval, S. Giri, and D. Suthar, Bioorg. Med. Chem. Lett. 21, 3103 (2011).
    [13] T. Vallianatou, G. Lambrinidis, C. Giaginis, E. Mikros, and A. Tsantili-Kakoulidou, Mol. Inform. 32, 431 (2013).
    [14] C. M. Dobson, Nature 432, 824 (2004).
    [15] C. S. Zheng, X. J. Xu, H. Z. Ye, G. W. Wu, X. H. Li, S. P. Huang, and X. X. Liu, Mol. Med. Report. 7, 1812 (2013).
    [16] L. Jiang, J. Chen, Y. He, Y. Zhang, and G. Li, J. Bioinform. Comput. Biol. 14, 1650005 (2015).
    [17] F. Azuaje, Biomed. Eng. Online 5, 51 (2006).
    [18] L. Jiang, X. Zhang, X. Chen, Y. He, L. Qiao, Y. Zhang, G. Li, and Y. Xiang, Molecules 20, 12769 (2015).
    [19] S. Sugunadevi, T. Sundarapandian, J. Shalini, K. Y. Jung, and L. K. Woo, Eur. J. Med. Chem. 45, 2132 (2010).
    [20] Y. Divya, P. Sarvesh, Y. Rakesh, P. Mahima, and P. Anubhuti, PLoS One 7, 822 (2012).
    [21] S. Tian, X. Zhou, H. Gong, X. Ma, and F. Zhang, Pharmacogn. Mag. 7, 4 (2011).
    [22] T. N. Doman, S. L. Mcgovern, B. J. Witherbee, T. P. Kasten, K. Ravi, W. C. Stallings, D. T. Connolly, and B. K. Shoichet, J. Med. Chem. 45, 2213 (2002).
    [23] Y. Kurogi and O. Guner, Curr. Med. Chem. 8, 1035 (2001).
    [24] O. Guner and O. Y. Clement, Curr. Med. Chem. 11, 2991 (2004).
    [25] L. Jun, L. J. Kennedy, S. Yan, T. Shiwei, Y. X. Yang, S. Y. Chen, W. Ying, A. S. Hernández, W. Wei, and P. V. Devasthale, J. Med. Chem. 53, 2854 (2010).
    [26] G. V. Dhoke, R. P. Gangwal, and A. T. Sangamwar, J. Mol. Struct. 1028, 22 (2012).
    [27] K. C. Chen, S. S. Chang, H. J. Huang, and T. L. Lin, J. Biomol. Struct. Dyn. 30, 662 (2012).
    [28] H. J. Huang, H. W. Lee KJYu, H. Y. Chen, F. J. Tsai, and C. Y. Chen, J. Biomol. Struct. Dyn. 28, 187 (2010).
    [29] S. Sundriyal and P. V. Bharatam, Eur. J. Med. Chem. 44, 3488 (2009).
    [30] W. Ji and B. Q. Gong, J. Ethnopharmacol. 119, 291 (2008).
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(908) PDF downloads(579) Cited by()

Proportional views
Related

Construction and Evaluation of Merged Pharmacophore Based on Peroxisome Proliferator Receptor-Alpha Agonists

doi: 10.1063/1674-0068/29/cjcp1602025

Abstract: Pharmacophore is a commonly used method for molecular simulation, including ligand-based pharmacophore (LBP) and structure-based pharmacophore (SBP). LBP can be utilized to identify active compounds usual with lower accuracy, and SBP is able to use for distinguishing active compounds from inactive compounds with frequently higher missing rates. Merged pharmacophore (MP) is presented to integrate advantages and avoid shortcomings of LBP and SBP. In this work, LBP and SBP models were constructed for the study of peroxisome proliferator receptor-alpha (PPARα) agonists. According to the comparison of the two types of pharmacophore models, mainly and secondarily pharmacological features were identified. The weight and tolerance values of these pharmacological features were adjusted to construct MP models by single-factor explorations and orthogonal experimental design based on SBP model. Then, the reliability and screening efficiency of the best MP model were validated by three databases. The best MP model was utilized to compute PPARα activity of compounds from traditional Chinese medicine. The screening efficiency of MP model outperformed individual LBP or SBP model for PPARα agonists, and was similar to combinatorial screening of LBP and SBP. However, MP model might have an advantage over the combination of LBP and SBP in evaluating the activity of compounds and avoiding the inconsistent prediction of LBP and SBP, which would be beneficial to guide drug design and optimization.

Lian-sheng Qiao, Yu-su He, Xiao-qian Huo, Lu-di Jiang, Yan-kun Chen, Xi Chen, Yan-ling Zhang, Gong-yu Li. Construction and Evaluation of Merged Pharmacophore Based on Peroxisome Proliferator Receptor-Alpha Agonists[J]. Chinese Journal of Chemical Physics , 2016, 29(4): 508-516. doi: 10.1063/1674-0068/29/cjcp1602025
Citation: Lian-sheng Qiao, Yu-su He, Xiao-qian Huo, Lu-di Jiang, Yan-kun Chen, Xi Chen, Yan-ling Zhang, Gong-yu Li. Construction and Evaluation of Merged Pharmacophore Based on Peroxisome Proliferator Receptor-Alpha Agonists[J]. Chinese Journal of Chemical Physics , 2016, 29(4): 508-516. doi: 10.1063/1674-0068/29/cjcp1602025
Reference (30)

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return